Peter Burgard

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7499488/publications.pdf

Version: 2024-02-01

43	1,911	279798	254184
papers	citations	23 h-index	43 g-index

51	51	51	2098
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Impact of glycogen storage disease type I on adult daily life: a survey. Orphanet Journal of Rare Diseases, 2021, 16, 371.	2.7	12
2	Differences of Phenylalanine Concentrations in Dried Blood Spots and in Plasma: Erythrocytes as a Neglected Component for This Observation. Metabolites, 2021, 11, 680.	2.9	3
3	William L.Nyhan, Georg F.Hoffmann. Atlas of inherited metabolic diseases (Hardcover and eâ€Book)4th ed. Boca Raton: <scp>CRC</scp> Press, Taylor & Francis Group, 2020, 855â€‰p., $175; Â£120, â‚¬124. <scp>ISBN</scp>â€13: 9781138196599. (With contributions from Aida I. Alâ€Aqeel and Bruce A. Barshop).. Journal of Inherited Metabolic Disease, 2021, 44, 284-284.	3.6	0
4	An Integrated clinical pathway for diagnosis, treatment and care of rare diseases: model, operating procedures, and results of the project TRANSLATE-NAMSE funded by the German Federal Joint Committee. Orphanet Journal of Rare Diseases, 2021, 16, 474.	2.7	7
5	Long-term Outcomes of Individuals With Metabolic Diseases Identified Through Newborn Screening. Pediatrics, 2020, 146, .	2.1	37
6	A holistic approach to the patients/ Families with inborn errors of metabolism. Medycyna Wieku Rozwojowego, 2020, 24, 65-72.	0.2	3
7	Allelic phenotype values: a model for genotype-based phenotype prediction in phenylketonuria. Genetics in Medicine, 2019, 21, 580-590.	2.4	48
8	Impairment of cognitive function in ornithine transcarbamylase deficiency is global rather than domainâ€specific and is associated with disease onset, sex, maximum ammonium, and number of hyperammonemic events. Journal of Inherited Metabolic Disease, 2019, 42, 243-253.	3.6	15
9	Impact of Diagnosis and Therapy on Cognitive Function in Urea Cycle Disorders. Annals of Neurology, 2019, 86, 116-128.	5.3	42
10	On being an editor, reviewer, and authorâ€”different sides of the same coin. Journal of Inherited Metabolic Disease, 2019, 42, 1-2.	3.6	6
11	High blood pressure, a red flag for the neonatal manifestation of urea cycle disorders. Orphanet Journal of Rare Diseases, 2019, 14, 80.	2.7	4
12	Evaluation of dietary treatment and amino acid supplementation in organic acidurias and ureaâ€cycle disorders: On the basis of information from a European multicenter registry. Journal of Inherited Metabolic Disease, 2019, 42, 1162-1175.	3.6	30
13	Decreased plasma l-arginine levels in organic acidurias (MMA and PA) and decreased plasma branched-chain amino acid levels in urea cycle disorders as a potential cause of growth retardation: Options for treatment. Molecular Genetics and Metabolism, 2019, 126, 397-405.	1.1	26
14	Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disordersâ€”A successful strategy for clinical research of rare diseases. Journal of Inherited Metabolic Disease, 2019, 42, 93-106.	3.6	35
15	Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disordersâ€”a successful strategy for clinical research of rare diseases. Journal of Inherited Metabolic Disease, 2019, 42, 93.	3.6	4
16	Urea Cycle Disorders in the US and Europe â€“ Evidence-based Clinical Outcomes Derived from Two Decades of Experience with Prospective Registry Studies. , 2019, 50, .		0
17	Biochemical markers and neuropsychological functioning in distal urea cycle disorders. Journal of Inherited Metabolic Disease, 2018, 41, 657-667.	3.6	31
18	Determinants of Plasma Docosahexaenoic Acid Levels and Their Relationship to Neurological and Cognitive Functions in PKU Patients: A Double Blind Randomized Supplementation Study. Nutrients, 2018, 10, 1944.	4.1	12

#	Article	IF	Citations
19	Development and Psychometric Evaluation of the MetabQoL 1.0: A Quality of Life Questionnaire for Paediatric Patients with Intoxication-Type Inborn Errors of Metabolism. JIMD Reports, 2017, 37, 27-35.	1.5	15
20	Issues with European guidelines for phenylketonuria. Lancet Diabetes and Endocrinology,the, 2017, 5, 681-683.	11.4	26
21	Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. Journal of Inherited Metabolic Disease, 2017, 40, 75-101.	3.6	173
22	Impact of age at onset and newborn screening on outcome in organic acidurias. Journal of Inherited Metabolic Disease, 2016, 39, 341-353.	3.6	60
23	Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders. Journal of Inherited Metabolic Disease, 2016, 39, 661-672.	3.6	52
24	Newborn Screening Programmes in Europe, Arguments and Efforts Regarding Harmonisation: Focus on Organic Acidurias. JIMD Reports, 2016, 32, 105-115.	1.5	17
25	Newborn Screening for Vitamin B6 Non-responsive Classical Homocystinuria: Systematical Evaluation of a Two-Tier Strategy. JIMD Reports, 2016, 32, 87-94.	1.5	19
26	Recurrent acute liver failure due to NBAS deficiency: phenotypic spectrum, disease mechanisms, and therapeutic concepts. Journal of Inherited Metabolic Disease, 2016, 39, 3-16.	3.6	92
27	Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disordersâ€”review and metaâ€analysis of observational studies published over more than 35 years. Journal of Inherited Metabolic Disease, 2016, 39, 219-229.	3.6	50
28	In vivo monitoring of urea cycle activity with 13C-acetate as a tracer of ureagenesis. Molecular Genetics and Metabolism, 2016, 117, 19-26.	1.1	5
29	Behavioural and emotional problems, intellectual impairment and healthâ€related quality of life in patients with organic acidurias and urea cycle disorders. Journal of Inherited Metabolic Disease, 2016, 39, 231-241.	3.6	29
30	A cross-sectional controlled developmental study of neuropsychological functions in patients with glutaric aciduria type I. Orphanet Journal of Rare Diseases, 2015, 10, 163.	2.7	10
31	Multifactorial modulation of susceptibility to l-lysine in an animal model of glutaric aciduria type I. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 768-777.	3.8	21
32	Biallelic Mutations in NBAS Cause Recurrent Acute Liver Failure with Onset in Infancy. American Journal of Human Genetics, 2015, 97, 163-169.	6.2	110
33	The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. Journal of Inherited Metabolic Disease, 2015, 38, 1041-1057.	3.6	186
34	The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. Journal of Inherited Metabolic Disease, 2015, 38, 1059-1074.	3.6	175
35	Networking Across Borders for Individuals with Organic Acidurias and Urea Cycle Disorders: The E-IMD Consortium. JIMD Reports, 2015, 22, 29-38.	1.5	26
36	Crossâ€sectional observational study of 208 patients with nonâ€classical urea cycle disorders. Journal of Inherited Metabolic Disease, 2014, 37, 21-30.	3.6	62

#	Article	IF	Citations
37	Living with an inborn error of metabolism detected by newborn screeningâ€"Parentsâ€™ perspectives on child development and impact on family life. Journal of Inherited Metabolic Disease, 2014, 37, 189-195.	3.6	34
38	Diagnosis and therapeutic monitoring of inborn errors of creatine metabolism and transport using liquid chromatographyâ€“tandem mass spectrometry in urine, plasma and CSF. Gene, 2014, 538, 188-194.	2.2	16
39	Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis. Orphanet Journal of Rare Diseases, 2013, 8, 167.	2.7	30
40	Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 â€“ From screening laboratory results to treatment, followâ€up and quality assurance. Journal of Inherited Metabolic Disease, 2012, 35, 613-625.	3.6	88
41	Efficacy and outcome of expanded newborn screening for metabolic diseases - Report of 10 years from South-West Germany *. Orphanet Journal of Rare Diseases, 2011, 6, 44.	2.7	128
42	Use of guidelines improves the neurological outcome in glutaric aciduria type I. Annals of Neurology, 2010, 68, 743-752.	5.3	147
43	Response. Pediatric Research, 2007, 61, 134-135.	2.3	0